MK-5475
Total Payments
$862,099
Transactions
56
Doctors
9
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $807,349 | 38 | 2 |
| 2019 | $54,750 | 18 | 9 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $782,034 | 23 | 90.7% |
| Consulting Fee | $78,865 | 25 | 9.1% |
| Travel and Lodging | $1,200 | 8 | 0.1% |
Payments by Type
Research
$782,034
23 transactions
General
$80,065
33 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Formulation Bridging Study of MK-5475 in Healthy Participants | Merck Sharp & Dohme Corporation | $742,404 | 0 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dose MK-5475 in Participants with Pulmonary Hypertension Associated with COPD | Merck Sharp & Dohme Corporation | $26,630 | 0 |
| A Study to Assess the Safety, Tolerability, and Pharmacodynamics of Multiple Dose MK-5475 in Participants with Hypoxemia Due To COVID-19 Pneumonia | Merck Sharp & Dohme Corporation | $13,000 | 0 |
Top Doctors Receiving Payments for MK-5475
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Knoxville, TN | $782,034 | 23 |
| , M.D | Internal Medicine | Charleston, SC | $32,690 | 16 |
| , MD | Internal Medicine | Boston, MA | $8,650 | 3 |
| , MD | Pulmonary Disease | Philadelphia, PA | $5,650 | 2 |
| , MD | Critical Care Medicine | Rochester, NY | $5,650 | 2 |
| , M.D | Internal Medicine | La Jolla, CA | $5,650 | 2 |
| , M.D., PH.D | Internal Medicine | Boston, MA | $5,650 | 2 |
| , MD | Internal Medicine | Buffalo, NY | $5,650 | 2 |
| , MD | Internal Medicine | Falls Church, VA | $5,650 | 2 |
| , M.D | Internal Medicine | Baltimore, MD | $4,825 | 2 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $862,099
Product Information
- Type Drug
- Total Payments $862,099
- Total Doctors 9
- Transactions 56
About MK-5475
MK-5475 is a drug associated with $862,099 in payments to 9 healthcare providers, recorded across 56 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2019 to 2020. In 2020, $807,349 was paid across 38 transactions to 2 doctors.
The most common payment nature for MK-5475 is "Unspecified" ($782,034, 90.7% of total).
MK-5475 is associated with 3 research studies, including "A Formulation Bridging Study of MK-5475 in Healthy Participants" ($742,404).